文献速递造血干细胞移植与细胞治疗

慢性GVHD患者非复发死亡率:慢性GVHD联盟更新分析

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
PubMed 文献 · Blood Adv · 2021-01-01

该研究基于慢性GVHD联盟两项前瞻性纵向观察研究中的937例患者,分析非复发死亡的危险因素与死因。中位随访4年,5年非复发死亡累积发生率为22%,预计12年增至40%;cGVHD是最常见死因(37.8%),其次为感染(17%)和呼吸衰竭(10%)。多因素分析显示减低强度预处理、较高总胆红素、NIH皮肤评分2-3分、NIH肺评分1-3分、较差的改良活动能力评分及步行距离缩短与非复发死亡风险增加显著相关。

要点

  • cGVHD患者非复发死亡不随时间平台化,12年预计达40%。
  • cGVHD本身(37.8%)和感染(17%)是最常见非复发死因。
  • 严重皮肤和肺部cGVHD与非复发死亡风险增加相关。

核心结论

  • cGVHD患者的非复发死亡不出现平台期而是随时间增加,最常见归因于GVHD或感染。
  • 严重皮肤和肺部cGVHD仍是与非复发死亡增加相关的挑战性表现。

研究设计与样本

  • 更新队列分析,纳入慢性GVHD联盟两项前瞻性纵向观察研究中的937例患者。
  • 分析患者、移植及cGVHD相关变量、危险因素和非复发死亡原因。
  • 存活者中位随访4年(范围0.1个月至12.5年)。

主要发现

  • 333例死亡中复发占25%。
  • 非复发死亡5年累积发生率为22%,12年预计为40%(95%CI 30%-50%)。
  • 中心报告cGVHD(37.8%)是非复发死亡最常见原因,常伴器官衰竭、感染或其他未特指原因。
  • 未提及cGVHD的死因中,感染占17%,呼吸衰竭占10%。
  • 多因素分析中非复发死亡风险增加与减低强度预处理、较高总胆红素、NIH皮肤评分2-3分、NIH肺评分1-3分、较差的改良活动能力评分及步行距离缩短显著相关。

关键数值与推荐

  • 非复发死亡5年累积发生率22%,12年预计40%(95%CI 30%-50%)。
  • cGVHD相关非复发死亡占37.8%,感染占17%,呼吸衰竭占10%。

临床怎么用

  • 对cGVHD患者应长期监测非复发死亡风险,尤其关注皮肤和肺部受累者。
  • 需开发不增加感染风险的新型治疗选择以改善严重皮肤和肺部cGVHD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. To better understand patients at highest risk for nonrelapse mortality (NRM), we analyzed patient-, transplant-, and cGVHD-related variables, risk factors, and causes of nonrelapse deaths in an updated cohort of 937 patients enrolled on 2 prospective, longitudinal observational studies through the Chronic GVHD Consortium. The median follow-up of survivors was 4 years (range, 0.1 months to 12.5 years). Relapse accounted for 25% of the 333 deaths. The cumulative incidence of NRM was 22% at 5 years, and it increased over time at a projected 40% (95% confidence interval, 30%-50%) at 12 years. Centers reported that cGVHD (37.8%) was the most common cause of NRM and was associated with organ failure, infection, or additional causes not otherwise specified. The next most frequent causes without mention of cGVHD were infection (17%) and respiratory failure (10%). In multivariable analysis, an increased risk for NRM was significantly associated with the use of reduced intensity conditioning, higher total bilirubin, National Institutes of Health (NIH) skin score of 2 to 3, NIH lung score of 1 to 3, worse modified Human Activity Profile adjusted activity score, and decreased distance on walk test. To summarize, cGVHD NRM does not plateau but increases over time and is most commonly attributed to GVHD or infection, presumably associated with immunocompromised status. Severe skin and lung cGVHD remain challenging manifestations associated with increased NRM, for which novel therapeutic options that do not predispose patients to infections are needed.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DeFilipp Z, Alousi AM, Pidala JA, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021. PMID: 34521116. doi:10.1182/bloodadvances.2021004941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。